Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy - Top-Institutions - MDSpire

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    City of Hope National Medical Center
    City of Hope National Medical Center

    Duarte, CA

    Key Differentiators

    • Oncology
    • Hematology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology
    • Hematology

Original Source(s)

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

  • by Maria D. Guerrero

  • May 6, 2026

Related Content

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody

  • May 5, 2026

  • 5 min
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Zoldonrasib in Patients With <em>KRAS</em> G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy

The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were pr...